Hillhouse Capital Management Ltd. Has $21,273,000 Holdings in Acceleron Pharma Inc. (XLRN)
Hillhouse Capital Management Ltd. held its position in Acceleron Pharma Inc. (NASDAQ:XLRN) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 700,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Acceleron Pharma comprises 0.3% of Hillhouse Capital Management Ltd.’s portfolio, making the stock its 23rd biggest holding. Hillhouse Capital Management Ltd. owned about 1.81% of Acceleron Pharma worth $21,273,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. New York State Common Retirement Fund grew its position in Acceleron Pharma by 11.7% in the 2nd quarter. New York State Common Retirement Fund now owns 34,300 shares of the biopharmaceutical company’s stock valued at $1,042,000 after acquiring an additional 3,599 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in Acceleron Pharma by 46.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock worth $51,127,000 after purchasing an additional 534,440 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Acceleron Pharma by 57.8% during the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 3,100 shares during the last quarter. BlackRock Inc. lifted its position in shares of Acceleron Pharma by 9.0% during the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock worth $121,719,000 after purchasing an additional 330,635 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its position in shares of Acceleron Pharma by 8.8% during the second quarter. Nationwide Fund Advisors now owns 24,737 shares of the biopharmaceutical company’s stock worth $752,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors own 77.35% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Hillhouse Capital Management Ltd. Has $21,273,000 Holdings in Acceleron Pharma Inc. (XLRN)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/hillhouse-capital-management-ltd-has-21273000-holdings-in-acceleron-pharma-inc-xlrn/1607031.html.
A number of analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Acceleron Pharma in a research note on Wednesday, September 20th. Barclays PLC upped their price target on shares of Acceleron Pharma from $42.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, September 20th. Royal Bank Of Canada assumed coverage on shares of Acceleron Pharma in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $44.00 price target on the stock. UBS AG reaffirmed a “buy” rating and issued a $50.00 price target (up previously from $36.00) on shares of Acceleron Pharma in a research note on Tuesday, September 12th. Finally, Cann reiterated a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $42.81.
In other news, CFO Kevin F. Mclaughlin sold 16,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $614,560.00. Following the completion of the transaction, the chief financial officer now owns 50,810 shares of the company’s stock, valued at $1,951,612.10. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP John D. Quisel sold 5,113 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total transaction of $196,441.46. Following the completion of the transaction, the senior vice president now directly owns 57,918 shares of the company’s stock, valued at approximately $2,225,209.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 66,578 shares of company stock valued at $2,518,117. 3.90% of the stock is currently owned by corporate insiders.
Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) opened at 37.88 on Wednesday. The stock’s market cap is $1.47 billion. The stock has a 50 day moving average of $36.68 and a 200 day moving average of $31.58. Acceleron Pharma Inc. has a 12 month low of $23.07 and a 12 month high of $41.69.
Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.69 million. During the same period in the previous year, the company posted ($0.59) EPS. Acceleron Pharma’s revenue was down 3.1% on a year-over-year basis. On average, equities analysts anticipate that Acceleron Pharma Inc. will post ($2.70) earnings per share for the current fiscal year.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.